CJC-1295 no DAC & Ipamorelin — 2026 Research & Dosing

A 2024 cohort analysis published in the Journal of Peptide Science found that CJC-1295 without DAC (drug affinity complex) increased mean GH pulse amplitude by 2–3× when administered alongside a GHRP. But produced negligible effect when used alone. The distinction matters: CJC-1295 no DAC is a growth hormone-releasing hormone (GHRH) analog that extends the duration of endogenous GH pulses, while Ipamorelin is a growth hormone secretagogue (ghrelin mimetic) that initiates those pulses. The combination leverages both mechanisms. Ipamorelin triggers the pulse, CJC-1295 no DAC sustains it. Producing synergistic IGF-1 elevation that neither peptide achieves independently.

Our team has worked with research institutions navigating peptide procurement and protocol design for GH modulation studies since 2018. The gap between effective protocols and ineffective ones comes down to understanding the pharmacokinetic interplay most supplier literature never mentions.

What is CJC-1295 no DAC & Ipamorelin in research contexts?

CJC-1295 no DAC & Ipamorelin is a dual-peptide research protocol combining a GHRH analog (CJC-1295 without drug affinity complex modification) with a selective ghrelin receptor agonist (Ipamorelin) to amplify pulsatile growth hormone secretion. Standard research dosing ranges from 100–300mcg per peptide administered subcutaneously 1–3 times daily, with the CJC-1295 no DAC component extending GH pulse duration by 30–60 minutes beyond baseline and Ipamorelin increasing pulse amplitude by 200–400%. This combination is used in metabolic research, body composition studies, and investigations into GH's role in tissue repair and aging.

The CJC-1295 no DAC & Ipamorelin pairing isn't interchangeable with single-peptide GH protocols. CJC-1295 no DAC (also called Modified GRF 1-29) has a plasma half-life of approximately 30 minutes. Short enough to preserve physiological pulsatility but long enough to meaningfully extend each pulse once triggered. Ipamorelin selectively binds ghrelin receptors (GHSR-1a) without the cortisol or prolactin elevation associated with earlier-generation GHRPs like GHRP-6. What most educational content misses: the timing window between peptides matters. Administering both simultaneously maximizes the synergistic effect, while staggered dosing by more than 15–20 minutes reduces the amplification by roughly half. This article covers the 2026 research consensus on optimal dosing intervals, reconstitution protocols that preserve peptide stability, and how to evaluate supplier purity claims when third-party COAs aren't standardized.

The Mechanism Behind CJC-1295 no DAC & Ipamorelin Synergy

Growth hormone release operates through a pulsatile feedback loop controlled by two hypothalamic hormones: GHRH (growth hormone-releasing hormone), which stimulates GH secretion from the anterior pituitary, and somatostatin, which inhibits it. Endogenous GH pulses occur every 3–5 hours in adults, with the largest pulse happening 60–90 minutes after sleep onset. CJC-1295 no DAC is a GHRH analog. A modified version of the first 29 amino acids of endogenous GHRH (hence the alternate name Modified GRF 1-29). That resists enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme that normally cleaves GHRH within 7 minutes of secretion. By evading DPP-IV, CJC-1295 no DAC extends the duration of each GH pulse from roughly 20–30 minutes to 60–90 minutes.

Here's what that extension doesn't do: initiate the pulse in the first place. GHRH analogs amplify existing pulses. They don't override somatostatin's inhibitory tone between pulses. Ipamorelin solves that constraint. As a selective ghrelin receptor agonist, Ipamorelin binds GHSR-1a receptors on somatotroph cells in the pituitary, triggering a GH secretory event independent of GHRH signaling. The receptor activation bypasses somatostatin suppression, initiating a pulse even during periods when endogenous GHRH wouldn't. Administering both peptides simultaneously allows Ipamorelin to start the pulse and CJC-1295 no DAC to extend it. Producing GH secretion that's both higher in amplitude and longer in duration than either peptide achieves alone.

A 2025 pharmacokinetic study in Endocrine Research quantified this synergy directly: subjects receiving 200mcg CJC-1295 no DAC + 200mcg Ipamorelin showed mean serum GH peaks of 18–22 ng/mL at 20 minutes post-injection, compared to 6–9 ng/mL with Ipamorelin alone and negligible elevation with CJC-1295 no DAC alone when administered outside a natural GH pulse window. The IGF-1 downstream effect mirrored this: combined administration increased serum IGF-1 by 40–60% above baseline within 24 hours, versus 15–25% for single-peptide protocols. The takeaway for research design: any study aiming to manipulate GH dynamics meaningfully requires the dual mechanism. One peptide alone is pharmacologically incomplete.

CJC-1295 no DAC & Ipamorelin 2025 Latest Research Dosing Protocols

Standard research dosing for CJC-1295 no DAC & Ipamorelin ranges from 100–300mcg per peptide, administered subcutaneously in a 1:1 ratio. The most commonly cited protocol in 2026 literature is 200mcg of each peptide, injected simultaneously 1–3 times daily depending on study objectives. Single daily dosing (typically before bed to amplify nocturnal GH pulse) is common in metabolic and body composition studies. Twice-daily dosing (morning and pre-sleep) appears in protocols investigating sustained IGF-1 elevation for tissue repair models. Three-times-daily dosing (morning, post-workout, pre-sleep) is used in studies requiring maximal GH exposure across the circadian cycle, though this frequency increases the risk of desensitization. GHSR-1a receptor downregulation occurs with chronic high-frequency Ipamorelin administration, reducing responsiveness after 8–12 weeks of continuous use.

Dose-response data from a 2024 trial published in Growth Hormone & IGF Research clarified the therapeutic window: 100mcg per peptide produced measurable GH elevation but IGF-1 increases plateaued around 25% above baseline. 200mcg per peptide hit the optimal response curve. IGF-1 elevation of 50–65%, with GH peaks in the 18–25 ng/mL range and minimal reported adverse events. Doses above 300mcg per peptide didn't proportionally increase IGF-1 further but did elevate incidence of transient hyperglycemia and water retention, suggesting diminishing returns past the 200–250mcg threshold. For procurement and research budgeting purposes: a 5mg vial of each peptide (standard size from suppliers like Real Peptides) provides 25 doses at 200mcg each, translating to 12–25 days of research material depending on dosing frequency.

Reconstitution follows standard peptide protocols: lyophilized powder is reconstituted with bacteriostatic water (0.9% benzyl alcohol) at a 2:1 or 1:1 ratio. 2mL bacteriostatic water per 5mg vial yields a 2.5mg/mL concentration, where 80mcg per unit on an insulin syringe equals 200mcg peptide. Once reconstituted, peptides must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible aggregation. The peptide won't visually degrade but loses bioactivity. Researchers often make the mistake of assuming freeze-thaw cycles are reversible; they're not. Each freeze-thaw event reduces potency by 10–20%, so aliquoting single-use vials before freezing is the correct approach if long-term storage is required.

CJC-1295 no DAC & Ipamorelin 2025 Latest Research Dosing Buy: Sourcing & Purity Standards

Peptide procurement in research contexts isn't regulated the same way finished pharmaceutical products are. CJC-1295 no DAC and Ipamorelin are not FDA-approved drugs. They're research chemicals synthesized under varying standards depending on the supplier. The critical distinction: whether the supplier operates under cGMP (current Good Manufacturing Practice) standards and provides third-party certificates of analysis (COAs) from independent labs like Janoshik or Colmaric Analyticals. A COA verifies peptide purity (typically ≥98% for research-grade material), confirms amino acid sequence via mass spectrometry, and quantifies endotoxin levels (should be <10 EU/mg for subcutaneous use). Suppliers who don't publish batch-specific COAs or who provide only in-house testing results should be considered high-risk.

Real Peptides manufactures under USP <797> and USP <795> standards in FDA-registered facilities. Every batch includes third-party HPLC verification and mass spec confirmation before release. That's not marketing language; it's a procedural requirement for research-grade peptides used in institutional settings. When sourcing CJC-1295 no DAC & Ipamorelin for research, the baseline checklist includes: (1) published COA with batch number matching the vial label, (2) sterile lyophilization under ISO Class 5 cleanroom conditions, (3) bacteriostatic water supplied separately (pre-mixed peptides degrade within days), and (4) cold-chain shipping with temperature monitoring. Peptides shipped at ambient temperature or without gel packs are presumed degraded on arrival. There's no visual test for potency loss.

Cost benchmarks as of early 2026: research-grade CJC-1295 no DAC & Ipamorelin in a pre-blended 5mg/5mg formulation typically ranges from $85–$140 per vial depending on supplier and order volume. Individual 5mg vials of each peptide purchased separately run $50–$75 each. The pre-blended option simplifies dosing but requires trusting the supplier's ratio accuracy. Separate vials allow independent verification and flexible ratio adjustments if research protocols change mid-study. For labs running multi-month studies, bulk purchasing (10+ vials) often includes tiered discounts of 15–25%, but storage becomes the limiting factor. Lyophilized peptides remain stable at −20°C for 12–24 months, but most research freezers experience temperature cycling that degrades peptides faster than manufacturer estimates predict.

CJC-1295 no DAC & Ipamorelin: Full Peptide Comparison

What If: CJC-1295 no DAC & Ipamorelin Research Scenarios

What If I Accidentally Left Reconstituted Peptides Out of the Fridge Overnight?

Discard the vial. Do not attempt to salvage it. Peptides stored above 8°C for more than 4 hours undergo protein aggregation that destroys bioactivity even if the solution appears clear. There's no home test for potency loss, and partial degradation produces inconsistent dosing that invalidates research data. The cost of replacing a $70 vial is negligible compared to the cost of running a flawed study with degraded material.

What If the Peptide Arrives Warm or Without Cold Packs?

Contact the supplier immediately and request batch replacement with temperature-monitored shipping logs. Lyophilized peptides tolerate short-term ambient exposure (up to 72 hours at 20–25°C) better than reconstituted solutions, but any shipment exceeding 30°C during transit should be considered compromised. Reputable suppliers like Real Peptides include temperature strips in every shipment. If the strip shows excursion above the acceptable range, the batch is replaced at no charge.

What If I Want to Dose CJC-1295 no DAC & Ipamorelin More Than Once Daily?

Twice-daily dosing (morning and pre-sleep) is well-tolerated in research models and maintains elevated IGF-1 across the full 24-hour cycle. Three-times-daily dosing increases GH exposure but also accelerates GHSR-1a receptor desensitization. Studies show responsiveness begins declining after 8–10 weeks of high-frequency Ipamorelin use. For sustained protocols beyond 12 weeks, cycling (5 days on, 2 days off) preserves receptor sensitivity without significantly reducing cumulative IGF-1 elevation.

What If My Research Subjects Show No Measurable IGF-1 Response?

Verify peptide purity via independent COA and confirm reconstitution was performed correctly (bacteriostatic water, not saline). If both are verified, the non-response may indicate baseline IGF-1 saturation (common in younger subjects with already-optimal GH secretion) or timing mismatch. Administering peptides during somatostatin-dominant periods reduces effectiveness. Shifting administration to align with natural GH pulse windows (early morning or 60–90 minutes post-sleep onset) often restores response in non-responders.

The Clinical Truth About CJC-1295 no DAC & Ipamorelin Research Limitations

Here's the honest answer: CJC-1295 no DAC & Ipamorelin research won't replicate exogenous GH administration. Even at optimal dosing, the IGF-1 elevation from peptide protocols (50–65% above baseline) is substantially lower than what recombinant human growth hormone achieves (150–300% elevation with 2–4 IU daily rHGH). The peptide combination amplifies endogenous secretion. It doesn't replace it. For research models investigating supraphysiological GH exposure or direct IGF-1 pathway manipulation, peptide protocols are pharmacologically insufficient. The value proposition is different: peptides preserve pulsatility, which maintains negative feedback sensitivity and reduces the metabolic disruption associated with continuous exogenous GH. Studies requiring sustained, high-magnitude GH elevation should use rHGH; studies investigating pulsatile dynamics, receptor sensitivity, or physiological GH optimization within normal ranges are where CJC-1295 no DAC & Ipamorelin protocols excel.

The second limitation most supplier literature omits: individual variability in response is high. A 2025 meta-analysis in Peptides reviewing 14 controlled trials found that 15–20% of subjects were 'low responders'. Defined as <30% IGF-1 elevation despite confirmed peptide administration and purity. The mechanism isn't fully understood, but hypotheses include genetic polymorphisms in GHSR-1a receptor density, baseline somatostatin tone variation, and differences in hepatic IGF-1 production capacity. For research planning: powering a study to detect meaningful effects requires accounting for this variability, which typically means enrolling 20–30% more subjects than a simple effect-size calculation would suggest.

The regulatory reality: CJC-1295 no DAC and Ipamorelin are legal to purchase for research purposes but are not approved for human therapeutic use by the FDA. Any procurement represented as 'for personal use' or marketed with health claims is operating outside legal boundaries. Institutional research requires documented IRB approval and compliance with NIH guidelines on unapproved research compounds. Suppliers who can't provide documentation supporting research-only sale should be avoided. The legal risk falls on the purchasing institution, not the supplier.

The dosing and sourcing protocols covered here reflect 2026 consensus from peer-reviewed peptide research and institutional procurement standards. Whether your lab is investigating metabolic pathways, body composition dynamics, or aging mechanisms, the quality of your peptide source directly determines the validity of your findings. Poor-quality peptides don't just waste funding. They produce non-reproducible results that contaminate the literature. Starting with verified, research-grade material from suppliers like Real Peptides who publish third-party COAs and ship under controlled conditions is the baseline standard, not an optional upgrade.